menu
    • menu
    [{"orgOrder":0,"company":"LianBio","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0.31,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.31,"dosageForm":"Capsule","sponsorNew":"LianBio \/ RA Capital","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ RA Capital"},{"orgOrder":0,"company":"LianBio","sponsor":"ReViral","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Sisunatovir","moa":"RSV fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LianBio","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"LianBio \/ ReViral","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ ReViral"},{"orgOrder":0,"company":"LianBio","sponsor":"Nanobiotix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Hafnium Oxide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"LianBio","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"LianBio \/ LIANBIO","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ LIANBIO"},{"orgOrder":0,"company":"LianBio","sponsor":"Lyra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"LianBio","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0.14999999999999999,"dosageForm":"Sustained Topical Implant","sponsorNew":"LianBio \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ LianBio"},{"orgOrder":0,"company":"LianBio","sponsor":"Landos Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LianBio","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"LianBio \/ LianBio","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ LianBio"},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ Not Applicable"},{"orgOrder":0,"company":"LianBio","sponsor":"MyoKardia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"LianBio \/ MyoKardia","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ MyoKardia"},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ Not Applicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Not Applicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Sisunatovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LianBio","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"LianBio \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ Pfizer"},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ Not Applicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ Not Applicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ Not Applicable"},{"orgOrder":0,"company":"LianBio","sponsor":"QED Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ QED Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ QED Therapeutics"},{"orgOrder":0,"company":"LianBio","sponsor":"Tarsus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"LianBio \/ Tarsus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Tarsus Pharmaceuticals"},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ Not Applicable"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"BBP-398","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ AstraZeneca"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BBP-398","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Astrazeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ Astrazeneca"},{"orgOrder":0,"company":"LianBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Not Applicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Hafnium Oxide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LianBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"LianBio","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Omilancor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LianBio \/ NImmune Biopharma","highestDevelopmentStatusID":"14","companyTruncated":"LianBio \/ NImmune Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by LianBio

    Menu

    LianBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : NImmune Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            NImmune Acquires Omilancor Rights for Asian Market Expansion

                            Details : Through the acquisition, NImmune will gain global rights to BT-11 (omilancor) along with the portfolio of immunoregulators. BT-11 is currently being assessed for the treatment of ulcerative colitis.

                            Brand Name : BT-11

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : NImmune Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hafnium Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nanobiotix Partner LianBio Assigns its Development and Commercialization Rights for NBTXR3 in China and Other ...

                            Details : Under the agreement, LianBio will assign to Janssen exclusive rights to develop and commercialize first-in-class radio enhancer NBTXR3 (hafnium oxide) in China, South Korea, Singapore, and Thailand for the treatment of locally advanced head and neck squa...

                            Brand Name : NBTXR3

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 26, 2023

                            Lead Product(s) : Hafnium Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharit...

                            Details : TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis via targeting and eradicating the root cause by selectively inhibiting the GABA-Cl channels.

                            Brand Name : TP-03

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 30, 2023

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavacamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $350.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets

                            Details : Under the agreement, BMS has obtained LianBio’s exclusive rights for Camzyos (mavacamten), the first and only cardiac myosin inhibitor approved, in Mainland China and Asia for the treatment of adults with symptomatic obstructive hypertrophic cardiomyop...

                            Brand Name : Camzyos

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 24, 2023

                            Lead Product(s) : Mavacamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $350.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBP-398,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimert...

                            Details : BBP-398 is a potential best-in-class SHP2 inhibitor being developed in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mut...

                            Brand Name : BBP-398

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2023

                            Lead Product(s) : BBP-398,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBP-398,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with ...

                            Details : The agreement aims to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an EGFR inhibitor, in Phase 1 clinical study for the treatment of patients with non-small cell lung can...

                            Brand Name : BBP-398

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 12, 2023

                            Lead Product(s) : BBP-398,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavacamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LianBio Announces Marketing Approval of CAMZYOS (mavacamten) in Singapore

                            Details : Camzyos (mavacamten), a cardiac myosin inhibitor, recently got approved in Macau for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

                            Brand Name : Camzyos

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 26, 2023

                            Lead Product(s) : Mavacamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Tarsus Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blephari...

                            Details : TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.

                            Brand Name : TP-03

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 08, 2023

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Tarsus Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : QED Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients wit...

                            Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven gastric cancer or gastroesophageal junction adenocarcinoma and to target achondroplasia at its source.

                            Brand Name : BGJ398

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2023

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : QED Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            LianBio

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavacamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR...

                            Details : Camzyos (mavacamten) is a cardiac myosin inhibitor, got recently approved in Macau fot the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

                            Brand Name : Camzyos

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 11, 2023

                            Lead Product(s) : Mavacamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth